Antibody Production Market for Clinical Laboratory services is expected to reach USD 33.57 billion by 2029, with a CAGR of 12.3 % between 2023 and 2029. Antibodies, or immunoglobulins, are large Y-shaped proteins generated by plasma cells and employed by the immune system to kill invaders including bacteria and viruses. The research gives a comprehensive perspective of the market by combining qualitative and quantitative data. It examines the global Antibody Production Market and provides forecasts for the key segments. It also includes market size and forecast estimates for five key regions: North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA), and South America, for the years 2023 to 2029. To know about the Research Methodology:-Request Free Sample Report
Antibody Production Market DynamicsMonoclonal antibodies (MAbs) are therapeutic antibodies used to treat cancer, autoimmune disorders, and inflammatory illnesses. The global need for monoclonal antibodies is increasing as infectious illnesses become more common. In the near future, healthcare reforms in emerging countries and increased investment in the antibody production market likely boost the market. Global market expansion is also being fuelled by rapid growth in the pharmaceutical and biotechnology sectors, increasing acceptance of protein therapies, and the availability of improved technology for antibody manufacturing. Since therapeutic antibodies have been the major therapy strategy for a range of ailments over the past 25 years, they are becoming increasingly significant. Significant technical advancements have expedited and enhanced the treatment of mAbs over this time. Since 2008, the US Food and Drug Administration (FDA) has approved 48 new monoclonal antibodies, bringing the entire worldwide market to 100 monoclonal antibodies in clinical usage by the end of 2022. Because of the rapid development of antibody therapeutics in recent decades, monoclonal antibodies have emerged as a key class of therapeutic agents in the treatment of a wide range of illnesses, including cancer, neurological disorders, and metabolic disorders. Revenue growth and regulatory acceptance of mAb therapies remained modest until the late 1990s when the first chimeric mAbs were approved. The rate of product approvals and revenue of mAb products has increased dramatically with the approval of humanized and then entirely human mAbs. The rapid expansion of mAb products is likely to be a major source of market growth. Major factors driving the global antibody production market growth include increasing research funding and biopharmaceutical company expansion. Healing antibodies are also approved for marketing by regulatory organizations. As the number of antigens increases, antibody manufacturing businesses will have more opportunities to develop new antibodies. The expanding incidence of infectious illnesses throughout the world, as well as the growing need for protein therapies, are driving the worldwide antibody production market. Restraints: issues such as the high cost of primary antibodies and the limited number of commercially accessible antibody medicines are projected to restrain overall market growth throughout the forecast period.
Antibody Production Market SegmentationBy Type, Monoclonal and polyclonal antibodies are the most common types of antibodies generated. Polyclonal antibodies are generated from distinct cells whereas monoclonal antibodies are clones of the original cell. When compared to polyclonal antibodies, monoclonal antibodies are the leading sector, with a CAGR of 11.2 percent. Infections, cancer, and other chronic disorders are becoming increasingly popular. Ion exchange chromatography is a typical technique for making monoclonal antibodies. This is because the process can be readily regulated and has a high capacity or purifying capability using this technology. Monoclonal and polyclonal cells are isolated using ammonium sulfate precipitation. By End-Use, The antibody production segment is divided into pharmaceutical and biotechnology corporations, research facilities, and others based on end-use. In 2022, pharmaceutical and biotechnology firms were reported to have the greatest revenue share of the market. The primary reason contributing to its greatest share is the widespread use of these goods in the manufacturing of antibodies. Additionally, because product purification is so important in the entire manufacturing process, corporations invest heavily in it. Owing to increased investment in antibody-based research and drug development, research laboratories were the second-highest revenue-generating sector of the market. During the forecast period, this segment is expected to grow at a considerable CAGR.
Antibody Production Market Regional InsightIn 2022, North America accounted for 32.3% of the global antibody production market. This is due to the presence of a number of biotechnology businesses in the area. Likewise, government spending on healthcare in North America is substantial. These elements all contribute to the market's expansion in this area. However, thanks to favourable policies and more innovation by enterprises in the Asia Pacific, the region is expected to grow at a faster rate during the forecast period. The availability of advantageous healthcare infrastructure, as well as the increased incidence of numerous chronic illnesses, are the primary drivers of market growth. Many biopharmaceutical and clinical research groups are targeting Asian nations for drug discovery and development, such as China and India. Less rigorous laws for antibody development and manufacturing, a large genome pool, and increasing healthcare infrastructure are only a few of the primary drivers driving the sector's rise in this region. As a consequence, over the forecast period, the Asia Pacific antibody manufacturing market would have the highest CAGR in sales. Major reasons are driving revenue growth in the Asia-Pacific market, including rising incidence of different chronic diseases, improved medical infrastructure and other facilities, and increased R&D efforts. Japan, Germany, and Canada are predicted to increase by 8.77 %, 9.81 %, and 10.46 %, respectively, over the forecast period. Europe is expected to grow significantly from 2023-to 2029 thanks to large corporations, increased frequency of infectious illnesses, and continued research efforts Report Objectives: • Landscape analysis of the Antibody Production Market • competitive benchmarking • Past and current status of the industry with the forecasted market size and trends • Evaluation of potential key players that include market leaders, followers, and new entrants • Technology trends • The potential impact of micro-economic factors on the market • External and Internal factors affecting the market have been analyzed The report also helps in understanding the Antibody Production Market dynamics, and structure by analysing the market segments to project the Antibody Production Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Antibody Production Market make the report investor’s guide.
Antibody Production Market Scope :Inquire before buying
Antibody Production Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2018 to 2022 Market Size in 2022: US $ 14.90 Bn. Forecast Period 2023 to 2029 CAGR: 12.3 % Market Size in 2029: US $ 33.57 Bn. Segments Covered: by Type Polyclonal antibody Monoclonal antibody Murine Chimeric Humanized by Process Upstream processing Downstream processing Filtration by End-Use Pharmaceutical and biotechnology companies Research laboratories Others
Antibody Production Market by RegionNorth America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)
Antibody Production Market: Key Players1. Cellab Gmbh 2. Eppendorf Ag 3. Merck Kgaa 4. Sartorius Ag 5. ProteoGenix 6. Genentech, Inc 7. BIOTEM 8. Eli Lily and Company 9. FiberCell Systems Inc. 10.Cellab GmbH 11.Sigma-Aldrich Corporation 12.Abca, PLC 13.Eppendorf AG, 14.Thermo Fisher Scientific Inc., 15.Pall Corporation Frequently Asked Questions 1. What is the projected market size & growth rate of the Antibody Production Market? Ans- The Antibody Production Market was valued at USD 14.90 billion in 2022 and is projected to reach USD 33.57 billion by 2029, growing at a CAGR of 12.3 % during the forecast period. 2. What are the key driving factors for the growth of the Antibody Production Market? Ans- Major factors driving the global antibody production market growth include increasing research funding and biopharmaceutical company expansion. 3. Which Region accounted for the largest Antibody Production Market share? Ans- In 2022, North America accounted for 32.3 % of the global antibody production market. 4. What makes the Asia Pacific a Lucrative Market for Antibody Production Market? Ans- The availability of advantageous healthcare infrastructure, as well as the increased incidence of numerous chronic illnesses, are the primary drivers of market growth. 5. What are the top players operating in the Antibody Production Market? Ans- Cellab Gmbh, Eppendorf Ag, Integra Bioscience Ag, Merck Kgaa, Sartorius Ag, ProteoGenix, and Genentech, Inc.
1. Global Antibody Production Market: Research Methodology 2. Global Antibody Production Market: Executive Summary 2.1 Market Overview and Definitions 2.1.1. Introduction to the Global Antibody Production Market 2.2. Summary 2.1.1. Key Findings 2.1.2. Recommendations for Investors 2.1.3. Recommendations for Market Leaders 2.1.4. Recommendations for New Market Entry 3. Global Antibody Production Market: Competitive Analysis 3.1 MMR Competition Matrix 3.1.1. Market Structure by region 3.1.2. Competitive Benchmarking of Key Players 3.2 Consolidation in the Market 3.2.1 M&A by region 3.3 Key Developments by Companies 3.4 Market Drivers 3.5 Market Restraints 3.6 Market Opportunities 3.7 Market Challenges 3.8 Market Dynamics 3.9 PORTERS Five Forces Analysis 3.10 PESTLE 3.11 Regulatory Landscape by region • North America • Europe • Asia Pacific • The Middle East and Africa • Latin America 3.12 COVID-19 Impact 4. Global Antibody Production Market Segmentation 4.1 Global Antibody Production Market, by Type (2022-2029) • Polyclonal antibody • Monoclonal antibody • Murine • Chimeric • Humanized 4.2 Global Antibody Production Market, by Process (2022-2029) • Upstream processing • Downstream processing • Filtration 4.3 Global Antibody Production Market, by End-Use (2022-2029) • Pharmaceutical and biotechnology companies • Research laboratories • Others 5. North America Antibody Production Market (2022-2029) 5.1 North American Antibody Production Market, by Type (2022-2029) • Polyclonal antibody • Monoclonal antibody • Murine • Chimeric • Humanized 5.2 North America Antibody Production Market, by Process (2022-2029) • Upstream processing • Downstream processing • Filtration 5.3 North America Antibody Production Market, by End-Use (2022-2029) • Pharmaceutical and biotechnology companies • Research laboratories • Others 5.4. North America Antibody Production Market, by Country (2022-2029) • United States • Canada • Mexico 6. European Antibody Production Market (2022-2029) 6.1. European Antibody Production Market, by Type (2022-2029) 6.2. European Antibody Production Market, by Process (2022-2029) 6.3 European Antibody Production Market, by End-Use (2022-2029) 6.4. European Antibody Production Market, by Country (2022-2029) • UK • France • Germany • Italy • Spain • Sweden • Austria • Rest Of Europe 7. Asia Pacific Antibody Production Market (2022-2029) 7.1. Asia Pacific Antibody Production Market, by Type (2022-2029) 7.2. Asia Pacific Antibody Production Market, by Process (2022-2029) 7.3 Asia Pacific Antibody Production Market, by End-Use (2022-2029) 7.4. Asia Pacific Antibody Production Market, by Country (2022-2029) • China • India • Japan • South Korea • Australia • ASEAN • Rest Of APAC 8. The Middle East and Africa Antibody Production Market (2022-2029) 8.1. Middle East and Africa Antibody Production Market, by Type (2022-2029) 8.2. Middle East and Africa Antibody Production Market, by Process (2022-2029) 8.3 Middle East and Africa Antibody Production Market, by End-Use (2022-2029) 8.4. Middle East and Africa Antibody Production Market, by Country (2022-2029) • South Africa • GCC • Egypt • Nigeria • Rest Of ME&A 9. Latin America Antibody Production Market (2022-2029) 9.1. Latin America Antibody Production Market, by Type (2022-2029) 9.2. Latin America Antibody Production Market, by Process (2022-2029) 9.3 Latin America Antibody Production Market, by End-Use (2022-2029) 9.4. Latin America Antibody Production Market, by Country (2022-2029) • Brazil • Argentina • Rest Of Latin America 10. Company Profile: Key players 10.1. Cellab Gmbh 10.1.1. Company Overview 10.1.2. Financial Overview 10.1.3. Global Presence 10.1.4. Capacity Portfolio 10.1.5. Business Strategy 10.1.6. Recent Developments 10.2. Cellab Gmbh 10.3. Eppendorf Ag 10.4. Integra Bioscience Ag 10.5. Merck Kgaa 10.6. Sartorius Ag 10.7. ProteoGenix 10.8. Genentech, Inc 10.9. BIOTEM 10.10. Eli Lily and Company 10.11. FiberCell Systems Inc. 10.12. Cellab GmbH 10.13. Sigma-Aldrich Corporation 10.14. Abca, PLC 10.15. Eppendorf AG, 10.16. Thermo Fisher Scientific Inc., 10.17. Pall Corporation